Skip to main content
. 2018 Feb 14;2018:8042838. doi: 10.1155/2018/8042838

Table 2.

Clinical pathological characteristics between different RDW + NLR groups.

Variables RDW + NLR = 0, n (%) RDW + NLR = 1, n (%) RDW + NLR = 2, n (%) P
Age 0.041
 ≤54 24 (23.3%) 20 (19.4%) 9 (8.7%)
 >54 14 (13.6%) 17 (16.5%) 19 (18.4%)
Gender 0.565
 Female 13 (12.6%) 16 (15.5%) 13 (12.6%)
 Male 25 (24.3%) 21 (20.4%) 15 (14.6%)
Tumor location 0.014
 Pyloric antrum 22 (21.4%) 21 (20.4%) 7 (6.8%)
 Nonpyloric antrum 16 (15.5%) 16 (15.5%) 21 (20.4%)
HER-2 0.867
 Positive 11 (10.7%) 11 (10.7%) 6 (5.8%)
 Negative 20 (19.4%) 15 (14.6%) 10 (9.7%)
 Unknown 7 (6.8%) 11 (10.7%) 12 (11.7%)
TNM stage 0.007
 I-II 11 (10.7%) 8 (7.8%) 1 (1.0%)
 III 13 (12.6%) 8 (7.8%) 4 (3.9%)
 IV 14 (13.6%) 21 (20.4%) 23 (22.3%)
Metastasis 0.001
 Yes 14 (13.6%) 21 (20.4%) 23 (22.3%)
 No 24 (23.3%) 16 (15.5%) 5 (4.9%)
RDW (%) <0.001
 ≤13.4% 38 (36.9%) 15 (14.6%) 0 (0.0%)
 >13.4% 0 (0.0%) 22 (21.4%) 28 (27.2%)
WBC (g/L) 0.001
 ≤5.69 22 (21.4%) 21 (20.4%) 9 (8.7%)
 >5.69 16 (15.5%) 16 (15.5%) 19 (18.4%)
MO (g/L) 0.830
 ≤0.42 21 (20.4%) 23 (22.3%) 9 (8.7%)
 >0.42 17 (16.5%) 14 (13.6%) 19 (18.4%)
NLR <0.001
 ≤2.755 38 (36.9%) 22 (21.4%) 0 (0.0%)
 >2.755 0 (0.0%) 15 (14.6%) 28 (27.2%)
CA125 (U/mL) 0.022
 ≤26.6 23 (22.3%) 22 (22.3%) 11 (10.7%)
 >26.6 15 (14.6%) 15 (14.6%) 17 (16.5%)
CA199 (U/mL) 0.042
 ≤11.9 23 (22.3%) 19 (18.4%) 14 (13.6%)
 >11.9 15 (14.6%) 18 (17.5%) 14 (13.6%)
CEA (μg/L) 0.190
 ≤2.4 21 (20.4%) 22 (21.4%) 11 (10.7%)
 >2.4 17 (16.5%) 15 (14.6%) 17 (16.5%)

RDW + NLR: combination of red blood cell distribution width and neutrophil-to-lymphocyte ratio; RDW: red cell distribution width; MO: monocyte; NLR: neutrophil-to-lymphocyte ratio. P less than 0.05 is statistically significant.